

Row No	REC Reference	IRAS	Name of Trial	Date of First	Date Site		HRA	Date Site	Date Site	Non-	Date Site	Source of Reasons for
				Patient	Invited	Selected	Approval	Confirmed	Confirmed	Confirmat	Ready To	delay
				Recruited			Date	By Sponsor		ion Status	Start	
1	16/EM/0240	203358	A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Paediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma	11/09/2017	05/08/2016	12/07/2017	11/10/2016	18/07/2017	18/07/2017		26/07/2017	
2	16/EE/0294	199550	ComparlsoN oF Optimal Hypertension RegiMens (Part of the Ancestry Informative Markers in Hypertension (AIM HY) Programme ? AIM HY-INFORM)	24/08/2017	29/06/2016	20/07/2017	01/11/2016	20/07/2017	21/07/2017		03/08/2017	
3	16/WM/0396	210511	A phase 3 randomized, open-label (sponsor-blind), activecontrolled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa		25/07/2016	24/07/2017	13/04/2017	03/08/2017	03/08/2017		11/09/2017	Neither
4	16/EM/0436	213166	SINGLE ARM, STUDY OF ALXN1210 IN COMPLEMENT INHIBITOR TREATMENT-NA?VE ADULT AND ADOLESCENT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)		11/10/2016	21/07/2017	07/12/2016	27/07/2017	28/07/2017		07/08/2017	Sponsor
5	17/NW/0145	217442	Longitudinal study of chronic wounds using novel wound measurement technologies	24/10/2017	31/01/2017	22/08/2017	21/08/2017	30/08/2017	30/08/2017		26/09/2017	
6	17/LO/0236	220765	PROMINENT PEMAFIBRATE TO REDUCE CARDIOVASCULAR OUTCOMES BY REDUCING TRIGLYCERIDES IN PATIENTS WITH DIABETES					28/07/2017			04/09/2017	
7	16/NW/0500	188072	A new speech and language therapy intervention for children who have Social Communication Disorder: feasibility and acceptability to service users and practitioners	05/07/2017	03/03/2017	05/07/2017	17/08/2016	06/07/2017	06/07/2017		06/07/2017	
8	16/WM/0512	218042	A Phase 1, Open-Label, Randomised, Repeat Dose, Parallel Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Ferric Maltol at Three Dosage Levels in Paediatric Subjects aged 10-17 years of age with iron deficiency (with or without anaemia)	30/08/2017	09/06/2017	18/07/2017	23/02/2017	07/08/2017	07/08/2017		08/08/2017	
9	17/WM/0110	212527	Paediatric Hepatic International Tumour Trial	06/11/2017	06/06/2017	30/08/2017	23/05/2017	01/09/2017	07/09/2017		20/09/2017	
10	17/NW/0235	224615	Treatment of cleft palate speech using a modified electropalatography (EPG) therapeutic technique: a case series		27/03/2017	18/07/2017	22/05/2017	18/07/2017	02/08/2017		08/08/2017	Sponsor
11	17/SC/0122	224090	AR101 TRIAL IN EUROPE MEASURING ORAL IMMUNOTHERAPY SUCCESS IN PEANUT ALLERGIC CHILDREN (ARTEMIS)	05/09/2017	09/05/2017	21/08/2017	18/04/2017	21/08/2017	22/08/2017		30/08/2017	
12	16/SC/0542	208245	A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION WHO HAVE COMPLETED A ROCHE-SPONSORED STUDY	21/09/2017	26/09/2016	22/08/2017	09/11/2016	24/08/2017	30/08/2017		13/09/2017	
13	16/LO/0998	192968	A diagnostic accuracy study to evaluate point of care lipase/pH test strip to confirm correct nasogastric position	24/10/2017	06/07/2017	15/08/2017	14/12/2016	22/08/2017	05/09/2017			
14	17/LO/0506	220370	A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 in Paediatric and Young Adult Patients with Relapsed Refractory B-cell Acute Lymphoblastic Leukaemia.	18/09/2017	12/01/2017	04/09/2017	05/07/2017	15/09/2017	18/09/2017		18/09/2017	
15	17/NW/0399	224760	STUDY OF THE MEASUREMENT OF VOLATILE AGENTS TO DIAGNOSE UROLOGICAL DISEASE	03/10/2017	14/07/2017	21/08/2017	25/07/2017	21/08/2017	30/08/2017		11/09/2017	
16	17/SC/0236	226436	Peanut Allergy oral immunotherapy study of AR101 for desensitisation in children and adults (Palisade) follow on study (ARC004)					14/08/2017			17/08/2017	
17	17/NI/0096	225743	HYDRATION FOR OPTIMAL PULMONARY EFFECTIVENESS					20/09/2017				Sponsor
18	17/SC/0016	218645	BMS CA209-743					18/09/2017			06/11/2017	NHS Provider
19	16/NW/0629	211995	The cystic fibrosis (CF) anti-staphylococcal antibiotic prophylaxis trial (CF START); a randomised registry trial to assess the safety and efficacy of flucloxacillin as a longterm prophylaxis agent for infants with CF.	22/03/2018	31/05/2017	01/09/2017	22/09/2016	29/09/2017	04/10/2017		11/01/2017	Sponsor
20	17/EM/0060	215678	I1F-MC-RHBY ?COAST extension		24/04/2017	05/12/2017	25/04/2017	28/06/2017	05/07/2017			Sponsor
21	16/SC/0655	212212	Knee Replacement Bandaging Study (KREBS)		04/05/2017	04/09/2017	08/02/2017	06/09/2017	11/10/2017		12/10/2017	
22	16/SC/0462	208830	DRAFFT 2 - Distal Radius Acute Fracture Fixation Trial 2	04/09/2017	17/05/2017			03/08/2017			18/08/2017	
23	16/WM/0448A	212745	Shire Solstice	16/10/2017	23/01/2017			23/05/2017			12/07/2017	Sponsor
24	17/LO/0794	223700	SPIRIT H2H		04/01/2017			28/07/2017			25/09/2017	Sponsor
25	17/LO/0683	226533	A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis	06/09/2017				23/08/2017			31/08/2017	
26	17/NW/0247	222303	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy		28/03/2017	17/11/2017		07/12/2017				Neither
27	17/NW/0440	230115	Family History Lifestyle	29/11/2017	05/07/2017			03/11/2017			13/11/2017	
28	17/NW/0504	212210	Routine usE of Cerebral Oximetry monitorinG iN cardlac SurgEry. A Randomised Controlled Single Centre Study to evaluate the use of neuromonitoring to identify and reduce postoperative complications (RECOGNISE)		27/07/2017	28/09/2017	28/09/2017	22/11/2017	29/11/2017		23/10/2017	Sponsor
29	17/YH/0055	215194	Multiple Interventions of Diabetic Foot Ulcer Treatment Trial	†	19/09/2017	19/09/2017	24/05/2017	11/10/2017	17/10/2017		27/10/2017	Sponsor

Division of Research & Innovation Page 1 of 5



											N
30	17/EM/0183	220783	A randomised, double-blind, parallel group PhIII study to assess the clinical efficacy and safety of 100 mg SC Mepolizumab as an add on to maintenance treatment in adults with severe bilateral nasal polyps		16/05/2017	11/09/2017	28/06/2017	19/09/2017	22/09/2017	02/01/2018	Sponsor
31	17/NW/0548	230870	Evaluation of the impact of varying size of catheter diameters on Anal Acoustic Reflectometry (AAR)		21/08/2017	23/11/2017	09/11/2017	24/11/2017	24/11/2017	24/11/2017	Sponsor
32	17/NW/0549	231440	parameters in the continent anal sphincter A Study of Anal Sphincter Function and the Recto-inhibitory Reflex (RAIR) in patients receiving General		21/09/2017	22/11/2017	20/10/2017	24/11/2017	24/11/2017	24/11/2017	Sponsor
32	17/11/0/0549	231440	Anaesthetic (GA) with Neuromuscular Blockade (NMB) using Anal Acoustic Reflectometry (AAR)		21/08/2017	25/11/2017	20/10/2017	24/11/2017	24/11/2017	24/11/2017	эропзог
33	17/NW/0547	230569	Anal Acoustic Reflectometry (AAR) and Recto-anal Inhibitory Reflex (RAIR) in the Assessment of Patients with Rectal Intussusception and Prolapse		21/08/2017	23/11/2017	20/10/2017	24/11/2017	24/11/2017	24/11/2017	Sponsor
34	17/YH/0313	232939	RelAxCough	18/12/2017	17/08/2017	01/11/2017	01/11/2017	01/11/2017	08/11/2017	29/11/2017	
35	17/LO/0182	213821	A Prospective, Randomized, Multicenter Controlled Trial of CERAMENT? G as Part of Surgical Repair of Open Diaphyseal Tibial Fractures	23/11/2017	14/07/2017	20/10/2017	30/03/2017	26/10/2017	27/10/2017	27/10/2017	
36	16/EE/0370	198596	MesoTRAP: A feasibility study comparing video-assisted thoracoscopic partial pleurectomy/decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial.		24/02/2017	05/12/2017	11/01/2017	22/11/2017	07/12/2017	11/12/2017	Neither
37	17/NW/0188	162347	The AAA Get Fit Trial: A Pilot Randomised Controlled Trial of Community Based Exercise to Improve Fitness and Reduce Morbidity and Mortality of Patients with Abdominal Aortic Aneurysm	08/11/2017	14/06/2017	27/10/2017	03/08/2017	01/11/2017	07/11/2017	07/11/2017	
38	17/EM/0063	213979	A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission		07/08/2016	19/09/2017	27/04/2017	06/10/2017	13/10/2017	17/11/2017	Neither
39	17/EM/0121	221773	A randomized, open, multinational, multicentre, 2-part study in spontaneously breathing preterm neonates with mild to moderate respiratory distress syndrome to investigate the safety, tolerability and efficacy of inhaled nebulised poractant alfa (porcine surfactant, curosurf?) in comparison with nCPAP alone		13/01/2017	06/12/2017	22/05/2017	07/12/2017	11/12/2017		Sponsor
40	17/NW/0127	218752	Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after failure of first-line therapy, followed by brentuximab + bendamustine (Bv + B) for participants with a suboptimal response. CheckMate 744: CHECKpoint pathway and nivolumab clinical Trial Evaluation		10/04/2017	02/10/2017	01/06/2017	24/10/2017	24/10/2017	29/11/2017	Neither
41	17/SC/0083	218035	A Prospective, Randomized, Open Label, Multi-center Study of the Safety and Pharmacokinetics of Apixaban versus Vitamin K Antagonist or LMWH in Pediatric Subjects with Congenital or Acquired Heart Disease Requiring Chronic Anticoagulation for Thromboembolism Prevention		13/02/2017	04/12/2017	07/07/2017	13/12/2017	14/12/2017	15/12/2017	Neither
42	17/NW/0209	213231	An open-label ascending dose cohort study to assess the safety, pharmacokinetics, and preliminary efficacy ofneoGAA (GZ402666) in patients with infantile-onset Pompe disease treated with alglucosidase alfa who demonstrateclinical decline or sub-optimal clinical response		27/10/2017	09/11/2017	18/05/2017	23/11/2017	24/11/2017	30/11/2017	Neither
43	16/NE/0325	199217	Eculizumab in Shiga-Toxin producing E. Coli Haemolytic Uraemic Syndrome (ECUSTEC): A Randomised, Double Blind, Placebo-Controlled Trial		16/09/2016	30/11/2017	05/06/2017	07/12/2017	14/12/2017	05/01/2018	Neither
44	17/YH/0076	208944	CALM- DIEM ? CONTROLLING AND LOWERING BLOOD PRESSURE WITH THE MOBIUSHD? ? DEFINING EFFICACY MARKERS		24/04/2017	06/11/2017	18/05/2017	08/11/2017	09/11/2017	01/12/2017	Neither
45	17/NS/0018	223787	FUTURE Study - Female Urgency, Trial of Urodynamics as Routine Evaluation; a superiority randomised clinical trial to evaluate the effectiveness and cost effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms.		17/05/2017	27/10/2017	11/08/2017	23/11/2017	28/11/2017	13/12/2017	Neither
46	17/NW/0529	226070	The Impact of Postoperative Packing of Perianal Abscess Cavities: a multicentre randomised controlled Trial (PPAC2)		16/08/2017	07/12/2017	05/12/2017		11/12/2017		Neither
47	17/SC/0237	220963	A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and pharmacokinetics of different doses of orally administered BI 1467335 during a12-week treatment period compared to placebo in patients with clinical evidence of NASH.		08/06/2017	10/11/2017	17/08/2017	14/12/2017	18/12/2017	22/12/2017	Neither
48	17/LO/0371	212841	Randomized, Assessor-Masked, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Comparison with 0.02% PHMB + 0.1% Propamidine Combination Therapy in Subjects Affected by Acanthamoeba keratitis	21/12/2017	21/06/2016	27/09/2017	19/06/2017	27/09/2017	19/10/2017	23/10/2017	Neither

Division of Research & Innovation Page 2 of 5



											NH
49	16/YH/0452	130824	PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA		27/06/2017	02/10/2017	09/12/2016	09/11/2017	16/11/2017	20/11/2017	Sponsor
50	17/EE/0204	207238	A randomized, double-blind, placebo-controlled, dose-ranging, study to evaluate the efficacy, safety and tolerability of single doses of BCX7353 as an acute attack treatment in subjects with hereditary angioedema		20/12/2016	17/11/2017	19/07/2017	28/11/2017	04/12/2017	14/12/2017	Neither
51	17/LO/0023	215490	MUK nine b: OPTIMUM. A phase II study evaluating multiple novel agentsoptimised combination of biological therapy innewly diagnosed high risk multiple myeloma and plasma cell leukaemia.		11/01/2017	31/10/2017	30/03/2017	06/11/2017	17/11/2017		Neither
52	17/LO/1088	228921	A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-termivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have a CFTR Gating Mutation		29/06/2017	03/11/2017	03/08/2017	30/11/2017	19/12/2017		Sponsor
53	17/EM/0239	228843	A phase II, open-label, non-controlled, intra-patient dose-escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, relapsed or treatment naive severe aplastic anemia or recurrent aplastic anemia		10/08/2017	30/11/2017	26/10/2017	05/12/2017	06/12/2017	13/12/2017	Neither
54	17/NE/0200	220486	Strategic MAnagement to Optimize Response To CardiacResynchronization Therapy Registry (SMART Registry)	06/11/2017	19/04/2017	11/09/2017	24/08/2017	16/10/2017	18/10/2017	20/10/2017	
55 56	17/LO/0041 17/NE/0136	219676 224520	CardioMEMS Heart Failure System "Outside US" Post-Approval Study A Long-Term Follow-up Study to Evaluate the Safety, Tolerability, and Efficacy of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B	18/10/2017				31/10/2017 16/10/2017		13/11/2017 16/10/2017	Sponsor
57	17/wm/0241	224978	Blood pressure monitoring in high risk pregnancy to improve the detection and monitoring of hypertension	29/11/2017	19/09/2017	02/10/2017	11/08/2017	19/10/2017	25/10/2017	28/11/2017	
58	16/LO/0878	201070	Prospective, multi-centre study to evaluate the everlinQ endoAVF System when used to create an endovascular arteriovenous fistula (endoAVF) for patients who require vascular access for haemodialysis.		09/08/2017	23/11/2017	16/09/2016	04/01/2018	08/01/2018	23/01/2018	Sponsor
59	17/NS/0106	230907	The hydrus microstent for refractory open-angle glaucoma: A prospective, multicenter clinical trial		18/10/2017	31/10/2017	05/12/2017	28/11/2017	05/12/2017	03/01/2018	Neither
60	16/WM/0448	212745	A Phase 3, Multicenter, Randomized, Open-label, Active-controlledStudy to Assess the Efficacy and Safety of Maribavir TreatmentCompared to Investigator-assigned Treatment in Transplant Recipientswith Cytomegalovirus (CMV) Infections that are Refractory or Resistantto Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir.		28/02/2017	08/12/2017	08/02/2017	14/12/2017		28/07/2017	Neither
61	17/WA/0347	234208	A randomised, double-blind, placebo-controlled, parallel-group, multicentre study to demonstrate the effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function		21/11/2017	12/03/2018	12/01/2018	12/03/2018	20/03/2018	11/04/2018	
62	17/EM/0324	225749			03/11/2017	12/03/2018	30/10/2017	21/03/2018	28/03/2018	12/04/2018	
63	17/EE/0474	229785	An Open-Label, Randomized, Multi-Center, Parallel Group, Two-Arm Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir versus Standard of Care for Treatment of Adenovirus Infections in High-Risk Pediatric Allogeneic Hematopoietic Cell Transplant Recipients.		13/06/2017	14/03/2018	05/01/2018	20/03/2018	21/03/2018	28/03/2018	Neither
64	17/WS/0267	234662	A multicentre randomised controlled trial, with nested process evaluation, to test the clinical and cost- effectiveness of self-management of vaginal pessaries to treat pelvic organ prolapse, compared to standard care to improve women's quality of life		01/10/2017	13/03/2018	09/03/2018	26/03/2018	28/03/2018		Neither
65	17/NW/0584	233211	A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of Serlopitant for the treatment of refractory chronic cough	07/03/2018	24/07/2017	04/01/2018	28/12/2017	08/01/2018	08/01/2018	08/02/2018	
66	17/SW/0221	232448	A randomized, partially-blinded, active-controlled,multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis		18/10/2017	08/01/2018	28/11/2017	08/01/2018	12/01/2018	16/02/2018	Neither
67	17/SS/0052	196827	Early Valve Replacement guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic Patients with Severe Aortic Stenosis		12/06/2017	19/03/2018	12/06/2017				
68	17/NW/0014	201841	A multicentre, randomised controlled pilot trial of standard care informed by results of an additional placental factor blood test versus standard care in women presenting with reduced fetal movement (RFM) at or after 36+0 weeks gestation.	21/03/2018	04/08/2016	11/01/2018	02/02/2017	11/01/2018	06/02/2018	12/03/2018	

Division of Research & Innovation Page 3 of 5



											NHS
69	17/EE/0038	217456	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RO7123520 AS ADJUNCT TREATMENT IN PATIENTS WITH MODERATELY TO		01/06/2017	29/01/2018	13/04/2017	07/03/2018	08/03/2018		Neither
			SEVERELY ACTIVE RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO TNF-a INHIBITORS								
70	17/NW/0639	233415	Post-market Study of the Endurant ChEVAR Technique for the treatment of Juxtarenal Aortic Aneurysms with a ShortInfrarenal Neck		27/06/2017	24/01/2018	22/01/2018	01/02/2018	05/02/2018	28/02/2018	Neither
71	15/LO/1835	111728	An international prospective study on clinically standardrisk medulloblastoma in children older than 3 years with lowrisk biological profile (PNET 5 MBLR) or averagerisk biological profile (PNET 5 MBSR) SIOP PNET 5 Medulloblastoma		17/07/2017	06/03/2018	20/10/2016	14/03/2018	03/04/2018		
72	17/WM/0308	226910	Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects with Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas aeruginosa (PA) Infection/Colonization		09/08/2017	22/02/2018	09/10/2017	04/04/2018	17/04/2018		Sponsor
73	17/LO/1174	229691	A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects withActive Non-Infectious Uveitis	21/02/2018	25/07/2017	05/01/2018	22/08/2017	05/01/2018	12/01/2018	18/01/2018	
74	17/WA/0394	174839	Evaluating the Clinical Utility of Face-Recognition Technology in Syndrome Diagnosis	06/02/2018	01/09/2017	26/01/2018	26/01/2018		30/01/2018	30/01/2018	
75	17/LO/0962	220190	Helping Pregnant smokers quit: A multi-centre RCT of electronic cigarettes and nicotine patches	21/02/2018	05/05/2017	09/01/2018	24/07/2017	25/01/2018	31/01/2018	12/02/2018	
76	17/LO/1502	232726	An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS443139 in Huntington?s Disease Patients Who Participated in Prior Investigational Studies of ISIS 443139	20/03/2018	20/09/2017	26/02/2018	09/11/2017	27/02/2018	28/02/2018	06/03/2018	
77	17/LO/1306	228268	A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogenic stem cell transplantation (REACH 3)		06/07/2017	08/01/2018	11/10/2017	08/01/2018	05/02/2018	08/02/2018	Neither
78	17/SC/0462	228889	A Randomized, Double-blind Phase 1/2a Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.preF in Adults 18 to 50 Years of Age and RSV-Seropositive Toddlers 12 to 24 Months of Age		06/10/2017	02/01/2018	04/10/2017	01/02/2018	01/02/2018	22/03/2018	Neither
79	17/EE/0481	226412	Pre-Implantation trial of Histopathology In renal Allografts Does the introduction of a national pre- implantation biopsy histopathology service increase numbers, and improve outcomes, of kidney transplants performed in the UK: an open, stepped-wedge cluster, randomised trial		08/11/2017	14/02/2018	05/01/2018	01/03/2018	01/03/2018		Sponsor
80	17/LO/1741	232904	Effectiveness and acceptability of myo-inositol nutritional supplement in the prevention of gestational diabetes: a pilotplacebo controlled double blind randomised trial	21/02/2018	17/11/2017	04/01/2018	29/12/2017	30/01/2018	31/01/2018	15/02/2018	
81	16/LO/2126	218039	A randomized trial comparing the ELUVIA? drug-eluting stent versus bare metal self-expanding nitinol stents in the treatment of superficial femoral and/or proximal popliteal arteries.		28/11/2017	22/01/2018	24/02/2017	02/02/2018	06/02/2018		Sponsor
82	17/SC/0391	227067	The High-volume Haemodiafiltration vs High-flux Haemodialysis Registry Trial	01/03/2018	22/11/2017	29/01/2018	07/09/2017	02/02/2018	06/02/2018	16/02/2018	
83	17/EE/0255	227279	VOLCANO 2	16/11/2017	06/03/2017	12/09/2017	26/07/2017	12/09/2017	15/09/2017	05/10/2017	
84	16/LO/0831	196728	Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia (CAP): a randomised controlled trial.		21/09/2017	16/03/2018	11/11/2016	16/04/2018	23/04/2018		Neither
85	17/WS/0187	220456	RANDOMISED INVESTIGATION OF THE MITRACLIP DEVICE IN HEART FAILURE: 2ND TRIAL IN PATIENTS WITH CLINICALLY SIGNIFICANT FUNCTIONAL MITRAL REGURGITATION		22/03/2018	02/05/2018	20/03/2018	18/04/2018	30/04/2018	15/05/2018	
86	18/NW/0255	241392	PROCalcitonin-based algorithm for antibiotic use in Acute Pancreatitis (PROCAP): A randomised controlled trial		10/01/2018	30/05/2018	29/05/2018		05/06/2018	05/06/2018	
87	16/LO/1211	207428	A Randomised, Double-blind, Parallel Group, Multicentre Study to Compare the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Efficacy of JHL1101 versus EU sourced MabThera? in Anti TNFInadequate Responder Patients with Moderate to Severe RA on Background MTX Therapy		08/01/2018	28/06/2018	25/08/2016	28/06/2018	10/07/2018		
88	18/SC/0055	239091	Evaluating the effect of immunisation with group B meningococcal vaccines on meningococcal carriage	25/04/2018	10/01/2018	09/04/2018	05/03/2018	09/04/2018	11/04/2018	19/04/2018	
89	16/LO/0913	186776	Corneal cross-linking versus standard care in children with keratoconus, a randomised, multicentre, observermaskedtrial of efficacy and safety		06/12/2017	19/04/2018	04/08/2016	02/05/2018	09/05/2018	10/05/2018	Neither
90	18/NE/0102	240702	A phase I, open?label, randomized, pharmacokinetic, pharmacodynamic, and safety study ofEtrolizumab followed by open?label extension and safety monitoring in paediatric patientsFrom 4 years to less than 18 years of age with moderate to severe ulcerative colitis orModerate to severe crohn?s disease		18/01/2018	06/06/2018	15/05/2018	08/06/2018	15/06/2018	18/06/2018	
91	17/NW/0649	227917	The ASsessment and Physiotherapy managEment of ataxia in Children following surgical resection of posterior fossa Tumour		12/12/2017	15/06/2018	24/10/2017	20/06/2018	06/07/2018	12/07/2018	

Division of Research & Innovation Page 4 of 5



											NHS
92	17/NE/0358	220871	Relative bioavailability and comparative pharmacokinetics of 13-CRA oral liquid and extracted capsule	05/06/2018	02/11/2017	13/04/2018	04/02/2018	09/05/2018	10/05/2018	16/05/2018	
			formulations: a randomised, open label, multi-dose, cross-over clinical trial in patients requiring treatment								
			cycles of 13-CRA.								
93	18/NE0103	241640	A Phase 3, randomized, double-blind, controlled study evaluating the efficacy and safety of VX-659	11/05/2018	09/02/2018	03/05/2018	02/05/2018	27/04/2018	09/05/2018	10/05/2018	
			combination therapy in subjects with cystic fibrosis who are homozygous for the F508del Mutation (F/F)								
94	17/LO/1060	187783	Randomised, double-blind, efficacy and mechanism study of sub-sensory sacral (Optimised) neuromodulation		31/08/2017	25/04/2018	29/09/2017	22/03/2018	28/03/2018	15/05/2018	
			in adults with faecal incontinence								
95	18/SC/0098	241440	A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple	27/06/2018	25/01/2018	11/05/2018	26/04/2018	22/05/2018	30/05/2018	30/05/2018	
			Myeloma Treatment Regimens								
96	16/SC/0502	199315	The ACL SNNAP Trial: ACL Surgery Necessity in Non Acute Patients. Comparison of the clinical and cost	29/05/2018	01/12/2017	12/04/2018	16/11/2016	24/04/2018	04/05/2018	29/05/2018	
			effectiveness of two management strategies for non-acute Anterior Cruciate Ligament (ACL) injury:								
			Rehabilitation versus surgical Reconstruction.								
97	17/YH/0262	219133	TReatment of Irritable bowel syndrome using Titrated ONdansetron Trial	19/06/2018	16/05/2017	25/04/2018	07/11/2017	25/04/2018	09/05/2018		
98	18/LO/0190	227705	Clinical investigation of the eyeWatch glaucoma drainage device	14/05/2018	13/03/2018	16/04/2018	27/03/2018	25/04/2018	09/05/2018	09/05/2018	
99	18/SW/0039	229163	Induction of labour for predicted macrosomia ?The Big Baby Trial?	, ,				20/06/2018		,,	
100	16/SC/0152	180853	Prevention of post-operative complications by using HMG-CoA Reductase Inhibitor in patients undergoing					26/09/2017		11/06/2018	Sponsor
	.,,.		oesophagectomy - A multicentre, randomised, double blind, placebo controlled trial		', , -	-, -, -	., .,	.,,	, , ,	, ,	.,
101	16/EM/0186	173279	Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo)Radiotherapy versus		19/01/2017	18/04/2018	31/10/2016	05/06/2018	21/06/2018		Sponsor
	==, =:::, ====		Total mesorectal excision for early REctal Cancer? STAR-TREC				,,	20, 20, 2020	,,		
102	18/NW/0083	226643	Comparison of 24 G versus 26 G peripheral intravenous safety cannula and a 24 G non- safety cannula in a	20/06/2018	29/03/2017	01/05/2018	19/04/2018		14/05/2018	14/05/2018	
	10,1111,0005	2200.5	population of neonates of less them 32 weeks gestation and less than 1.5 kg birth weight	20,00,2010	23,03,201,	01,03,2010	15/0./2010		11,03,2010	11,00,2010	
			population of recordees of less them 32 weeks gestation and less than 1.5 kg birth weight								
103	17/EM/0404	223875	A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of		29/11/2016	11/04/2018	22/02/2018	02/05/2018	09/05/2018	20/06/2018	Sponsor
	=:,=::,=::		SHP640 (PVP-lodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-lodine and			,,	,,	,,	,,	,,	
			Placebo in the Treatment of Adenoviral Conjunctivitis								
104	17/EM/0405	223871	A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of		29/11/2016	11/04/2018	12/03/2018	02/05/2018	09/05/2018	20/06/2018	Sponsor
20.	17,211,0103	223071	SHP640 (PVP-lodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the		23/11/2010	11,01,2010	12,03,2010	02, 03, 2010	03, 03, 2010	20,00,2010	эролзол
			Treatment of Bacterial Conjunctivitis								
105	17/LO/0243	219613	A randomized, double-blind, multi-dose, placebo-controlled study to evaluate the efficacy, safety and		25/09/2017	27/03/2018	27/03/2017	15/06/2018	18/06/2018	21/06/2018	Sponsor
	17,20,02.0	213013	tolerability of GSK 2330672 administration for the treatment of pruritus in patients with primary biliary		20,03,201,	27,03,2010	27,03,2017	15,00,2010	10,00,2010	21,00,2010	эролзол
			cholangitis.(GLIMMER:GSK2330672 triaL of lbat inhibition with Multidose Measurement for Evaluation of								
			Response).								
106	16/EE/0324	203951	A Phase II Prospective Trial of Prophylactic Donor Lymphocyte Infusions for the Prevention of Relapse post		20/10/2017	18/05/2018	08/09/2016	20/06/2018	25/06/2018	27/06/2018	
			HSCT in patients with High Risk Myeloid Malignancy				,,				
107	17/YH/0389	222882	A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab In Patients Aged =6		25/07/2017	25/04/2018	12/12/2017	25/04/2018	11/05/2018	04/06/2018	
	, , ,		Months to <6 Years With Severe Atopic Dermatitis			-, - ,	, , -	.,.,	, ,	, , , , , , , , , , , , , , , , , , ,	
108	17/SC/0582	234404	A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL		24/10/2017	02/05/2018	18/01/2018	26/05/2018	01/06/2018	12/06/2018	
	_:, -:, -:-		DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY		_ ,, _ ,, _ ,	,,			,,	,,	
109	17/YH/0426	231118	A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab		08/12/2017	29/05/2018	24/01/2018	29/05/2018	14/06/2018		
	, ,-		Administered Concomitantly with Topical Corticosteroids in Patients, =6 Years to <12 Years Of Age, with		, , , ,	,,	, . ,	, ,			
			Severe Atopic Dermatitis								
110	17/EM/0152	216307	A Multi-center, Randomised, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib	1	18/10/2016	19/06/2018	21/07/2017	19/06/2018	12/07/2018		
	, ,		Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML	1	, ., .,	, , , , , , , , , , , , , , , , , ,	, . ,	-, -, -,0	, , ,		
111	17/NW/0389	226274	A Pilot randomised controlled trial comparing efficacy of Continuous Very Low Energy Diet (C-VLED) to	30/01/2018	23/05/2017	13/11/2017	14/08/2017	13/11/2017	01/12/2017	04/12/2017	Sponsor
	,,		Intermittent Very Low Energy Diet (I-VLED) in patients with Type 2 Diabetes	,, , , , , , , , , , , ,	, 55, 252,	,,,,	,,,	-,,+,	- ,,	,,	-
112	16/NS/0106	212541	Reducing Asthma Attacks in Children using Exhaled Nitric Oxide as a biomarker to inform treatment strategy -	13/06/2018	24/08/2017	02/02/2018	04/04/2017	03/03/2018	27/03/2018	25/04/2018	Sponsor
	-, -,		a randomised trial (RAACENO)	-,,	, ,	, , , , , , , , , , , ,	, . ,	., ,	, ,	-, -,	-1
				1						I	

Division of Research & Innovation Page 5 of 5